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Chronic obstructive pulmonary disease (COPD) is characterised by chronic inflammation in
pulmonary tissue and is also associated with systemic effects.
The objective of this study was determination of lymphocyte subpopulation and the
expression of Fas receptor on lymphocytes derived from peripheral blood of patients with
stable COPD (n ¼ 18) and a control group: asymptoma˛atic smokers (n ¼ 12) and non-
smokers (n ¼ 12). Flow cytometry method with monoclonal antibodies was used for
evaluation of lymphocyte subsets: CD4+ and CD8+ and the expression of Fas (CD95) on T
lymphocytes.
We found an elevated proportion of CD8+ cells in the blood of COPD patients. Proportion of
Fas+ T lymphocytes was significantly higher in patients with COPD when compared with
asymptomatic smokers and non-smokers (mean: 84.4% vs. 71.6% vs. 61.0% for Fas+/ CD4+
and 88.1% vs. 73.8% vs. 58.3% for Fas+/CD8+ lymphocytes). The proportion of Fas positive
CD8+ cells significantly correlated with the degree of airway obstruction and hypoxemia.
The significant correlations of Fas positive CD4+ and Fas positive CD8+ with smoking history
expressed as pack years smoked were observed.
Our observation of an elevated proportion of circulating lymphocytes bearing Fas receptor
may play a role in induction of these cells’ apoptosis and indicate the role of Fas/ FasL
pathway in the changes in proportion of lymphocyte subpopulations in patients with COPD.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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u.pl (J. Domagała-Kulawik).Introduction
Chronic obstructive pulmonary disease (COPD) is a progres-
sive disorder, characterised by poorly reversible airway
obstruction and persistea˛nt inflammation in the lung tissue.1
One of the major risk factors for developing COPD is
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Fas+/CD8+ lymphocytes in COPD 1339cigarette smoking but the reason why only about 15%
smokers develop COPD remains unclear. The participation
of neutrophils, macrophages and CD8 positive lymphocytes
in the airways inflammation of smokers and patients with
COPD was well documented.2,3 Recently, many data suggest
that COPD is a systemic disorder accompanied by chronic
inflammation and a well-documented role of TNF-a/
neutrophil axis in the disease progression.4 A few studies
have been published on the alternations in the population of
circulating T- cells in COPD showing an increase in the
proportion of CD8+ cells in blood of patients with COPD.5–7
Activation and programmed death (apoptosis) of these cells
in COPD are of interest. One of the important inducers of
apoptosis is Fas/Fas ligand (FasL) system. Fas (APO -1, CD95)
bearing cells are capable of apoptosis. The expression of Fas
is regulated by many factors (for example by hypoxia).8 The
aim of our study was to evaluate the proportion of
lymphocyte subpopulations and the expression of Fas
receptor on lymphocytes obtained from peripheral blood
of patients with COPD with special account to CD4+ and
CD8+ subpopulations. We used flow cytometry method. Data
were compared with healthy non-smokers and asymptomatic
smokers. We analysed the relationship between the propor-
tion of Fas positive cells and the results of pulmonary
function tests and the influence of tobacco smoke on these
cells population.Material and methods
Study participants
In this prospective study 18 patients with stable COPD, 12
asymptomatic smokers and 12 healthy non-smokers were
included. The diagnosis of COPD was established according
to the ATS/ERS standards.1 Pulmonary function tests were
performed according to the ATS/ERS standards (abc PNEU-
MO, abcMED, Poland, Vmax 229, Sensormedix).1 The group
of COPD patients consisted of 8 women and 10 men, all
smokers. Twelve asymptomatic smokers (5 women, 7 men)Table 1 Demographic data and results of pulmonary function
control groups (data expressed as mean7SD).
Subjects COPD
n 18
Age 71710*
Pack years 52737
FEV1
L 1.0270.4*
% predicted 44.5720.6*
FVC
L 2.170.7*
% predicted 69.9717.1*
FEV1 %FVC 49.4710.5*
RV (% predicted) 205.6740.4
PaO2 (mmHg) 67.377.5
PaCO2 (mmHg) 40.376.1
Plethysmography was performed only in patients with COPD. All
measurements of arterial blood gases were not performed.with normal values of pulmonary function tests and and 12
never smoking healthy volunteers (10 women and 2 men)
served as control groups. Demographic data of subjects and
results of pulmonary function tests are presented in the
Table 1. None of the subjects had symptoms of infection or
exacerbation of the disease during the study. None received
glycocorticosteroids at the time of the study. Patients with
any chronic disease other than COPD and with malignant
disease were excluded from this investigation. The study
was approved by the Ethics Committee of the Warsaw
Medical University.Flow cytometry analysis
The analysis of Fas expression was performed on lympho-
cytes from venous blood. The following mixtures of
antibodies were used for cell phenotyping: anti-CD45-FITC
and anti-CD14-PE, negative isotype controls (Ig2a-FITC and
Ig2b-PE), anti-CD4-FITC and anti-CD95-PE, anti-CD8-FITC
and anti-CD95-PE (Becton-Dickinson Immunocytometry Sys-
tems, San Jose, California). Two-colour analysis of cells was
performed as described previously.10 Anti- CD45- FITC and
anti- CD14- PE was used for the lymphocyte gate setting at
FSC/SSC graph. The samples were analysed by a FACS
Calibur flow cytometer (Becton-Dickinson, San Jose, Cali-
fornia). The cells were collected by CELLQuest software.
Figure 1 presents an example of dot plots showing double
staining for CD4/ CD95 and CD8/ CD95 lymphocytes in
patients with COPD.Statistical analysis
For data comparison the ANOVA (for data normally dis-
tributed) and Kruskal–Wallis (for data non-normally distrib-
uted) tests were used. If the test was significant the post hoc
Newman– Keulus analysis was made. The relationships
between the proportion of cells and the results of pulmonary
function tests and between proportion of cells and the
number of pack-years smoked were examined by thetests and arterial blood gases of patients with COPD and
Asymptomatic smokers Healthy nonsmokers
12 12
54716 4076*
33723 0
2.871.2* 3.0570.5*
95.8711.8* 96.079.0*
3.471.2* 3.470.8*
10378.4* 93710.5*
76.475.0* 87.877.0*
— —
— —
— —
healthy persons had O2 saturation more than 97% and the
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Figure 1 Flow cytometry profile of peripheral blood (PB) lymphocytes: lymphocytes CD95+/CD4+ in the upper right quadrant (left
picture), lymphocytes CD95+/CD8+ in the upper right quadrant (right picture).
Table 2 Proportion of CD4+ ,CD8+,CD4+ positive for CD95+ and CD8+positive for CD95+ lymphocytes as percentage of all
lymphocytes no AND- and CD4+: CD8+ ratio in the peripheral blood of patients with COPD and both control groups:
asymptomatic smokers and healthy non-smokers.
COPD patients (n ¼ 18) Asymptomatic smokers (n ¼ 12) Healthy non-smokers (n ¼ 12)
CD4+ (%) 39.9 (26.6–44.8) 42.7 (39.0–51.1) 43.1 (39.0–45.6)
CD4+/ CD95+ (%) 30.4 (22.8–37.8) 29.9 (25.3–38.4) 26.4 (20.4–29.6)
CD8+ (%) 35.4z (28.1–53.1) 26.4z (23.3–29.9) 30.2 (24.3–40.5)
CD8+/ CD95+ (%) 33.6,y (25.6–40.1) 20.7 (17.6–30.6) 21.3y (12.9–32.9)
CD4+: CD8+ 1.06 (0.61–1.52) 1.65 (1.23–1.95) 1.30 (0.82–1.83)
Data expressed as median (p25–p75).
Significant difference between patients with COPD and asymptomatic smokers, Po0.05.
ySignificant difference between patients with COPD and healthy non-smokers, Po0.05.
zP ¼ 0:07.
J. Domagała-Kulawik et al.1340Spearman rank correlation coefficient. Correlations with
both RX0.4 and a Po0.05 were considered relevant.Results
The proportion of CD8+ lymphocytes in the PB of COPD
patients was higher than in healthy smokers (P ¼ 0:07) and
the CD4+: CD8+ ratio was significantly lower in the blood of
patients when compared with healthy smokers, as was
shown in the Table 2. There was an elevated proportion of
CD8+ lymphocytes with expression of Fas (CD95) in the
peripheral blood of patients when compared with healthy
persons (Table 2). In Fig. 2 we showed the median proportion
of Fas+ CD4+ lymphocytes as percentage of the whole pool
of CD4+ lymphocytes and in Fig. 3 the proportion of Fas+
CD8+ lymphocytes as percentage of the whole pool of CD8+
lymphocytes. The proportion of Fas positive CD4+ lympho-
cytes was higher in COPD patients when compared with
healthy smokers and non-smokers. The proportion of Fas
positive CD8+ lymphocytes was also higher in patients when
compared with healthy persons. All of these differences
were statistically significant (Po0.05). No difference was
found in the proportion of Fas positive cells in the
population of CD4+ lymphocytes when compared with theproportion of Fas positive cells in the population of CD8+
lymphocytes in the group of patients and in the group of
healthy persons.
The mean age in the patients group was higher than in the
control groups. Influence of age on proportion of lymphocyte
subpopulations cannot be excluded. We performed the
following analysis: cases younger than 40 yr and older than
75 yr were rejected. The results of statistical analysis are
shown in the Table 3. The differences in the proportion of
Fas positive cells between investigated groups remained
significant.
We found a negative correlation of the proportion of CD8+
lymphocytes with FEV1%FVC (R ¼ 0:57, P ¼ 0:06) and
positive correlation of CD4/CD8 ratio with FEV1%FVC
(R ¼ 0:47, not significant). The proportion of Fas positive
CD8 cells significantly correlated with depletion of
FEV1%FVC (R ¼ 0:6, Po0.05) and with an arterial blood
oxygen pressure (PaO2) (R ¼ 0:57, Po0.05).
There was a significant correlation of Fas positive CD4+
cells and Fas positive CD8+ cells with mean pack years
smoked in the whole group of smokers (R ¼ 0:57, Po0.05,
R ¼ 0:46, Po0.05, respectively, Fig. 4). These correlations
were significant in the group of asymptomatic smokers. In
the group of patients with COPD no correlation of proportion
of lymphocytes with smoking history was found.
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Figure 2 Proportion of CD4+ cells with expression of Fas in the blood of patients, asymptomatic smokers and healthy non-smokers
(median values, p25–p75), cells with expression of CD95 as percentage of all CD4+ cells.*Po0.05.
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Figure 3 Proportion of CD8+ cells with expression of Fas in the blood of patients, asymptomatic smokers and healthy non-smokers
(median values, p25–p75), cells with expression of CD95 as percentage of all CD8+ cells.
Table 3 Proportion of Fas positive CD4 cells (as proportion of all CD4 cells) and Fas positive CD8 cells (as proportion of all
CD8 cells) of COPD patients and healthy persons in comparable age.
Group Mean age (range) Fas+CD4+ cells Fas+CD8+ cells
Nonsmokers (n ¼ 7) 55 (47–69) 68.6 (58.8–71.0) 65.0 (57.9–88.7)
asymptomatic smokers (n ¼ 10) 59 (40–76) 70.6 (60.2–77.9)y 73.0 (64.6–77.3)y
patients with COPD (n ¼ 13) 66 (54–76) 86.2 (74.3–90.3),y 86.7 (82.7–91.7),y
Data expressed as median (p25–p75).No significant differences in the age of subjects were found.
Significant difference between patients with COPD and healthy nonsmokers, P ¼ 0:018.
ySignificant difference between patients with COPD and asymptomatic smokers, P ¼ 0.016.
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Figure 4 Correlation between proportion of Fas positive CD8+ cells with mean pack years smoked in the whole investigated group
(R ¼ 0:46, Po 0.05).
J. Domagała-Kulawik et al.1342Discussion
In this study we found an elevated proportion of CD8+ cells,
lower CD4:CD8 ratio and an elevated proportion of both
lymphocyte subptypes: CD4+ and CD8+ with the expression
of ‘‘death receptor’’— Fas derived from peripheral blood of
patients with COPD. Two control group were included:
healthy non-smokers and asymptomatic smokers without
bronchial obstruction. We found significant correlations of
Fas positive CD4+ cells and Fas positive CD8+cells with
smoking history and of Fas positive CD8+ cells with the
degree of airflow limitation and hypoxemia. To the best of
the author’s knowledge, there are only few data on this
subject in the literature.
An elevated proportion of CD8+ lymphocytes in the site of
chronic inflammation: in the airways and lung parenchyma
in patients with COPD was observed previously. It was
concluded that CD8+ lymphocytes play a crucial role in the
pathogenesis of airway inflammation in smokers with
bronchial obstruction.3 Recently, many data confirm the
role of systemic inflammation in COPD and the augmentation
of neutrophils and the neutrophils cytokine network in the
circulation of patients with COPD was found.4 However little
is known about the role of lymphocytes in this process. We
found an elevated proportion of CD8+ cells in the peripheral
blood of patients with COPD. Similar results were reported
by other investigators.5–7 However in the study of Kim et al.
and of Glader et al. the differences between patients and
healthy were not significant.5,7 De Jong et al.6 reported a
significantly elevated proportion of CD8+ cells in patients
with COPD but only in non-smokers. In our study, a negative
correlation of the proportion of CD8+ cells and a positive
correlation of CD4/ CD8 ratio with FEV1%FVC were observed.
Kim et al.5 presented similar results. We did not observe any
significant correlation of the proportion of CD8+ cells with
FEV1 but we considered FEV1%FVC to be a representative
and stable parameter in grading of bronchial constriction in
COPD.1
The main exogenous agent in the pathogenesis of COPD is
tobacco smoke but the reason why only about 15% smokers
develop COPD remains unclear. In our study the proportionof CD8+ cells in the blood of asymptomatic smokers was
lower than in patients with COPD and in non-smokers. In
other studies the proportion of CD8+ cells in peripheral
blood was stable (within normal values), while an increase
of in the proportion of these cells in the airways of
asymptomatic smokers was observed.6,7,9,10 It seems that
there is a predominance of local inflammation in the airways
of smokers without COPD. There is no evidence of systemic
inflammation in these subjects as observed in patients with
COPD. Thus our observation suggests that tobacco smoke
may not be the only factor responsible for the augmentation
of circulating CD8+ cells in patients with COPD and that
other factors play a role in the pathogenesis of systemic
inflammation in COPD. Interestingly, de Jong et al. reported
a significantly increased proportion of peripheral blood CD8+
cells in non-smoking individuals with COPD, but there was no
distinction between never and ex-smokers and the group
was analysed as a whole.6 In the present study no difference
in the proportion of cells between active and ex-smokers
with COPD was found (data not shown). In our previous study
we demonstrated, that chronic inflammation in the course
of COPD persists after smoking cessation.11
In this study we found a significantly elevated proportion
of lymphocytes with expression of Fas in patients with COPD
when compared with healthy smokers and non-smokers. The
Fas protein belongs to the TNF family and is known to be up-
regulated after cell’s activation. Fas/Fas ligand (FasL)
system is an inducer of apoptosis and plays a role in the
elimination of activated lymphocytes.8,12 The present
observation agrees with a study of Hodge et al. who found
an increased rate of lymphocyte apoptosis and Fas expres-
sion on CD4 and CD8 lymphocytes in patients with COPD.
They concluded that persistent inflammation in COPD is a
result of increased apoptosis of once stimulated lympho-
cytes and of the impairment in clearance of apoptotic
material.13 In the study of Yasuda et al. an increased
concentration of soluble sFas, was found in the peripheral
blood of patients with severe COPD.14 sFas is known to be an
inhibitor of apoptosis and an elevated concentration of this
agent have been observed in the sites of immune cell’s
activation.12 In our study we focused on the CD8+ cells
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receptor was elevated, but also the proportion of CD4+/Fas+
was significantly higher in patients with COPD in comparison
with healthy subjects. The CD4+ cells are necessary in the
activation and maturation of CD8+ cells. Furthermore, the
role of CD4+ lymphocytes in the elimination of CD8+ cells
using Fas/ FasL pathway was postulated.15,16 Recently, many
data suggest that autoimmne reaction in the development of
inflammation in COPD is possible.17–19 Increased Fas expres-
sion on lymphocytes may be an element of response to any
antigenic stimulus.
In our previous study we observed an elevated proportion
of Fas+ lymphocytes in patients with lung cancer.20 Tobacco
smoke is one of the main causal agent in COPD and lung
cancer as well. Activation of CD8+ cytotoxic cells was
observed in both diseases.18,21 In a recent study, Glader et
al. presented an elevated proportion of activated T cells in
current smokers with and without COPD.7 Data concerning
the influence of smoking on apoptosis of immune cells are
conflicting. Tobacco smoke was shown to inhibit neutrophils
apoptosis.22 Bijl et al. observed increased Fas bearing
lymphocyte subsets: CD4+, CD8+ and B-cells in smokers
compared with non-smoking persons what was confirmed by
our observations.23 Additionally, the correlation of Fas
positive lymphocytes with the number of pack-years smoked
was observed by us only in the group of smokers without
bronchial obstruction, not in the group of patients with
COPD. This observation may indicate that other agent
(agents) in addition to tobacco smoke may be involved in
the activation and apoptosis of lymphocytes in patients with
COPD and disorder this direct relationship between tobacco
smoke exposure and a number of T cells observed in healthy
smokers.
In conclusion, the results of our study confirmed the
participation of CD8+ lymphocytes and CD4+ cells, in the
systemic inflammation in patients with COPD. Elevated
proportion of Fas bearing lymphocytes in the blood of these
patients may indicate the role of Fas/ Fas L pathway in the
population changes of these cells.
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